All News

Patients with relapsed/refractory multiple myeloma may now receive talquetamab following the agent’s accelerated approval by the FDA.

Patients with metastatic RET fusion-positive non–small cell lung cancer may now be treated with pralsetinib, which has been granted regular approval by the FDA.

Continuing multidisciplinary discussions during the chemotherapy shortage is important for delivering the best possible care for each patient with breast cancer, according to Maryam Lustberg, MD, MPH.

Data from the phase 2 FIRE-4.5 trial suggest that cetuximab further reinforces a bevacizumab-based chemotherapy regimen as the frontline treatment of choice for BRAF-mutant, metastatic colorectal cancer.

The safety profile of selpercatinib in patients with RET fusion–positive non–small cell lung cancer in the phase 3 LIBRETTO-431 study is comparable with previous reports.

Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.

Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.

The safety profile of upifitamab rilsodotin in the phase 1b/2 UPLIFT trial is consistent with prior reports of the agent in those with platinum-resistant ovarian cancer.

The therascreen PDGFRA RGQ PCR kit has become the first FDA-approved companion diagnostic designed to detect platelet-derived growth factor receptor alpha gene mutations.

Michael Ganio, PharmD, MS, BCPS, FASHP, addresses some challenges concerning the ongoing chemotherapy shortage in the United States, and how communication among clinical teams may mitigate it.

Using the 31-gene expression profile assay may help lead to more personalized treatment strategies in patients with cutaneous melanoma, according to Aaron Farberg, MD.

Investigators plan to launch a controlled trial assessing remestemcel-L in the highest-risk adults with steroid-refractory acute graft-versus-host-disease to meet the FDA’s request for additional data.

Findings from a phase 1 trial highlight the potential tolerability and efficacy of ABM-1310 as a treatment for patients with BRAF-mutated solid tumors.

Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.

While there is a cisplatin shortage in the United States, the FDA has approved the importation of select chemotherapy drugs from China to help mitigate the scarcity of the agents.

Combined with chemotherapy, blinatumomab appears tolerable and beneficial in a subgroup of pediatric patients with B-cell acute lymphoblastic leukemia in first relapse but does not yield better survival outcomes in the overall population.

Patients at high risk for breast cancer appear to have higher rates of nonadherence to screening guidelines vs those at average risk.

Brian Van Tine, MD, PhD, states that sitravatinib appears to be active and well tolerated among patients with dedifferentiated or well-differentiated liposarcoma.

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, discusses what strategies are being used to treat patients with bladder cancer during the chemotherapy shortage.

The reduction of hematologic adverse effects with trilaciclib may improve clinical outcomes in patients with extensive-stage small cell lung cancer, according to Jerome Goldschmidt, MD.

Findings from a previous phase 1/2a trial demonstrate that zipalertinib is a potential treatment option for pretreated patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations.

Among patients with low-grade, non–muscle invasive bladder cancer, intravesical UGN-102 appears to improve outcomes vs standard surgical treatment in two phase 3 trials.

Brian Van Tine, MD, PhD, also discusses how the treatment of desmoid tumors has evolved following data supporting the use of sorafenib in this population.

Dostarlimab plus chemotherapy produces notable benefits among patients with advanced, mismatch repair deficient endometrial cancer in the phase 3 RUBY trial.

Investigators note that although therapy-related myelodysplastic syndromes or acute myeloid leukemia are not common, efforts to reduce treatment-associated toxicity in survivors of lymphoid neoplasms are needed given the poor prognosis associated with the diagnosis.

Treatment with batiraxcept plus paclitaxel did not produce any new safety signals among patients with platinum-resistant ovarian cancer in the phase 3 AXLerate-OC trial.

CAR T-cell therapies and immunotherapy agents may offer up new options and even become standard of care in certain sarcoma subtypes.

Investigators of a retrospective study report that an AI deep learning model may also predict negative margin probabilities better than conventional modalities.

Levels of soluble CD163 appear to be higher in those with p53 abnormalities, elevated lactate dehydrogenase, and low hemoglobin in a study cohort of patients with mantle cell lymphoma.

Results from the phase 3 SUNLIGHT trial support the approval of trifluridine/tipiracil plus bevacizumab in patients with previously treated, metastatic colorectal cancer.